S Heinonen1, L Saarinen2, J Naukkarinen3, A Rodríguez4, G Frühbeck4, A Hakkarainen5, J Lundbom5, N Lundbom5, K Vuolteenaho6, E Moilanen6, P Arner7, S Hautaniemi2, A Suomalainen8, J Kaprio9, A Rissanen10, K H Pietiläinen11. 1. Obesity Research Unit, Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland. 2. Research Programs Unit, Genome-Scale Biology and Institute of Biomedicine, Biochemistry and Developmental Biology, Helsinki, Finland. 3. 1] Obesity Research Unit, Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland [2] FIMM, Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland. 4. Metabolic Research Laboratory, Clinica Universidad de Navarra, & CIBERobn, Instituto de Salud Carlos III, Pamplona, Spain. 5. Helsinki Medical Imaging Center, University of Helsinki, Helsinki, Finland. 6. The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland. 7. Lipid Laboratory, Department of Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden. 8. Research Program of Molecular Neurology and Department of Neurology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland. 9. 1] FIMM, Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland [2] Finnish Twin Cohort Study, Department of Public Health, Hjelt Institute, University of Helsinki, Helsinki Finland [3] National Institute for Health and Welfare, Department of Mental Health and Substance Abuse Services, Helsinki, Finland. 10. Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland. 11. 1] Obesity Research Unit, Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland [2] FIMM, Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland [3] Department of Medicine, Division of Endocrinology, Helsinki University Central Hospital, Helsinki, Finland.
Abstract
BACKGROUND: Adipocyte size and number have been suggested to predict the development of metabolic complications in obesity. However, the genetic and environmental determinants behind this phenomenon remain unclear. METHODS: We studied this question in rare-weight discordant (intra-pair difference (Δ) body mass index (BMI) 3-10 kg m(-2), n=15) and concordant (ΔBMI 0-2 kg m(-)(2), n=5) young adult (22-35 years) monozygotic twin pairs identified from 10 birth cohorts of Finnish twins (n=5 500 pairs). Subcutaneous abdominal adipocyte size from surgical biopsies was measured under a light microscope. Adipocyte number was calculated from cell size and total body fat (D × A). RESULTS: The concordant pairs were remarkably similar for adipocyte size and number (intra-class correlations 0.91-0.92, P<0.01), suggesting a strong genetic control of these measures. In the discordant pairs, the obese co-twins (BMI 30.6 ± 0.9 kg m(-2)) had significantly larger adipocytes (volume 547 ± 59 pl), than the lean co-twins (24.9 ± 0.9 kg m(-)(2); 356 ± 34 pl, P<0.001). In 8/15 pairs, the obese co-twins had less adipocytes than their co-twins. These hypoplastic obese twins had significantly higher liver fat (spectroscopy), homeostatic model assessment-index, C-reactive protein and low-density lipoprotein cholesterol than their lean co-twins. Hyperplastic obesity was observed in the rest (7/15) of the pairs, obese and lean co-twins having similar metabolic measures. In all pairs, Δadipocyte volume correlated positively and Δcell number correlated negatively with Δhomeostatic model assessment-index and Δlow-density lipoprotein, independent of Δbody fat. Transcripts most significantly correlating with Δadipocyte volume were related to a reduced mitochondrial function, membrane modifications, to DNA damage and cell death. CONCLUSIONS: Together, hypertrophy and hypoplasia in acquired obesity are related to metabolic dysfunction, possibly through disturbances in mitochondrial function and increased cell death within the adipose tissue.
BACKGROUND: Adipocyte size and number have been suggested to predict the development of metabolic complications in obesity. However, the genetic and environmental determinants behind this phenomenon remain unclear. METHODS: We studied this question in rare-weight discordant (intra-pair difference (Δ) body mass index (BMI) 3-10 kg m(-2), n=15) and concordant (ΔBMI 0-2 kg m(-)(2), n=5) young adult (22-35 years) monozygotic twin pairs identified from 10 birth cohorts of Finnish twins (n=5 500 pairs). Subcutaneous abdominal adipocyte size from surgical biopsies was measured under a light microscope. Adipocyte number was calculated from cell size and total body fat (D × A). RESULTS: The concordant pairs were remarkably similar for adipocyte size and number (intra-class correlations 0.91-0.92, P<0.01), suggesting a strong genetic control of these measures. In the discordant pairs, the obese co-twins (BMI 30.6 ± 0.9 kg m(-2)) had significantly larger adipocytes (volume 547 ± 59 pl), than the lean co-twins (24.9 ± 0.9 kg m(-)(2); 356 ± 34 pl, P<0.001). In 8/15 pairs, the obese co-twins had less adipocytes than their co-twins. These hypoplastic obese twins had significantly higher liver fat (spectroscopy), homeostatic model assessment-index, C-reactive protein and low-density lipoprotein cholesterol than their lean co-twins. Hyperplastic obesity was observed in the rest (7/15) of the pairs, obese and lean co-twins having similar metabolic measures. In all pairs, Δadipocyte volume correlated positively and Δcell number correlated negatively with Δhomeostatic model assessment-index and Δlow-density lipoprotein, independent of Δbody fat. Transcripts most significantly correlating with Δadipocyte volume were related to a reduced mitochondrial function, membrane modifications, to DNA damage and cell death. CONCLUSIONS: Together, hypertrophy and hypoplasia in acquired obesity are related to metabolic dysfunction, possibly through disturbances in mitochondrial function and increased cell death within the adipose tissue.
Authors: C Weyer; J K Wolford; R L Hanson; J E Foley; P A Tataranni; C Bogardus; R E Pratley Journal: Mol Genet Metab Date: 2001-03 Impact factor: 4.797
Authors: M Lehtovirta; K H Pietiläinen; E Levälahti; K Heikkilä; L Groop; K Silventoinen; M Koskenvuo; J Kaprio Journal: Diabetologia Date: 2010-04-17 Impact factor: 10.122
Authors: Elisabet Arvidsson Nordström; Mikael Rydén; Emma C Backlund; Ingrid Dahlman; Maria Kaaman; Lennart Blomqvist; Barbara Cannon; Jan Nedergaard; Peter Arner Journal: Diabetes Date: 2005-06 Impact factor: 9.461
Authors: Maya Styner; Gabriel M Pagnotti; Cody McGrath; Xin Wu; Buer Sen; Gunes Uzer; Zhihui Xie; Xiaopeng Zong; Martin A Styner; Clinton T Rubin; Janet Rubin Journal: J Bone Miner Res Date: 2017-05-04 Impact factor: 6.741
Authors: M Muniandy; S Heinonen; H Yki-Järvinen; A Hakkarainen; J Lundbom; N Lundbom; J Kaprio; A Rissanen; M Ollikainen; K H Pietiläinen Journal: Int J Obes (Lond) Date: 2017-04-25 Impact factor: 5.095
Authors: K H Pietiläinen; K Ismail; E Järvinen; S Heinonen; M Tummers; S Bollepalli; R Lyle; M Muniandy; E Moilanen; A Hakkarainen; J Lundbom; N Lundbom; A Rissanen; J Kaprio; M Ollikainen Journal: Int J Obes (Lond) Date: 2015-10-26 Impact factor: 5.095
Authors: E Järvinen; K Ismail; M Muniandy; L H Bogl; S Heinonen; M Tummers; S Miettinen; J Kaprio; A Rissanen; M Ollikainen; K H Pietiläinen Journal: Int J Obes (Lond) Date: 2015-11-25 Impact factor: 5.095
Authors: S Bollepalli; S Kaye; S Heinonen; J Kaprio; A Rissanen; K A Virtanen; K H Pietiläinen; M Ollikainen Journal: Int J Obes (Lond) Date: 2017-10-05 Impact factor: 5.095